Last reviewed · How we verify

NCT03608592: ARDS

Human Umbilical Cord Mesenchymal Stem Cells (MSCs) Therapy in ARDS

Status unknown NA Last updated 4 September 2019
What this trial tests

NA trial testing umbilical cord derived mesenchymal stem cells (UCMSCs) suspension in Acute Respiratory Distress Syndrome in 26 participants. Status unknown.

Timeline
1 June 2018
Primary endpoint
1 August 2020
1 December 2020

Quick facts

Lead sponsorSun Yat-sen University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment26
Start date1 June 2018
Primary completion1 August 2020
Estimated completion1 December 2020
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Sun Yat-sen University

Who can join

18 and older, any sex, with Acute Respiratory Distress Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute respiratory distress syndrome (ARDS) is a devastating inflammatory and destructive disease in critical ill patients. Preclinical studies have shown a promising perspective of mesenchymal stem cells (MSCs) therapies in ARDS. But the safety and efficacy of umbilical cord MSCs (UCMSCs) have not yet been convinced in clinical trails. This study will explore the safety and life-rescue potential of UCMSCs in refracotry ARDS.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Reducing mortality from 2019-nCoV: host-directed therapies should be an option.
    Zumla A, Hui DS, Azhar EI, Memish ZA, et al · · 2020 · cited 288× · PMID 32035018 · DOI 10.1016/s0140-6736(20)30305-6
  2. Pharmacological agents for adults with acute respiratory distress syndrome.
    Lewis SR, Pritchard MW, Thomas CM, Smith AF. · · 2019 · cited 128× · PMID 31334568 · DOI 10.1002/14651858.cd004477.pub3
  3. Emerging pharmacological therapies for ARDS: COVID-19 and beyond.
    Horie S, McNicholas B, Rezoagli E, Pham T, et al · · 2020 · cited 69× · PMID 32654006 · DOI 10.1007/s00134-020-06141-z
  4. Current understanding of the therapeutic benefits of mesenchymal stem cells in acute respiratory distress syndrome.
    Lopes-Pacheco M, Robba C, Rocco PRM, Pelosi P. · · 2020 · cited 61× · PMID 31485828 · DOI 10.1007/s10565-019-09493-5
  5. COVID-19 and lung cancer: risks, mechanisms and treatment interactions.
    Addeo A, Obeid M, Friedlaender A. · · 2020 · cited 44× · PMID 32434788 · DOI 10.1136/jitc-2020-000892
  6. The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as Immunomodulatory Agents for COVID-19 Patients.
    Alzahrani FA, Saadeldin IM, Ahmad A, Kumar D, et al · · 2020 · cited 42× · PMID 33014070 · DOI 10.1155/2020/8835986
  7. Genetically modified mesenchymal stem cell therapy for acute respiratory distress syndrome.
    Han J, Liu Y, Liu H, Li Y. · · 2019 · cited 36× · PMID 31843004 · DOI 10.1186/s13287-019-1518-0
  8. Mesenchymal Stem Cell-Derived Exosomes Exhibit Promising Potential for Treating SARS-CoV-2-Infected Patients.
    Raghav A, Khan ZA, Upadhayay VK, Tripathi P, et al · · 2021 · cited 35× · PMID 33799966 · DOI 10.3390/cells10030587

Verify or expand the search:

Other recruiting trials for Acute Respiratory Distress Syndrome

Currently open trials in the same condition.

Other Sun Yat-sen University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03608592.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing